Posted: 03/09/2020
The corporate team at Penningtons Manches Cooper is advising Stanford Capital and SI Capital as joint brokers to ImmuPharma plc on a £6.5 million equity placing of new ordinary shares.
ImmuPharma is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. Its portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE).
Admission of the new shares is expected to occur on 7 September 2020.
London-based corporate partner, Seb Orton, is leading on this deal with assistance from associate Hannah Shamsolmaali.
© 2024 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear
Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority under number 419867.
Return to news headlines 